Ignite Creation Date:
2025-12-26 @ 10:44 PM
Ignite Modification Date:
2025-12-26 @ 10:44 PM
Study NCT ID:
NCT05382312
Status:
COMPLETED
Last Update Posted:
2025-10-07
First Post:
2022-05-16
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-26
Start Date Type:
ACTUAL
Primary Completion Date:
2025-05-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-05-27
Completion Date Type:
ACTUAL
First Submit Date:
2022-05-16
First Submit QC Date:
None
Study First Post Date:
2022-05-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-02
Last Update Post Date:
2025-10-07
Last Update Post Date Type:
ESTIMATED